Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?

European Journal of Cancer · Elsevier

Аннотация

Publication date: 9 December 2026 Source: European Journal of Cancer, Volume 249 Author(s): Patrick Neven, Francois Duhoux, Philippe Aftimos, Patrick Berteloot, Evandro de Azambuja, Cleo De Backer, Debbie Debaere, Françoise Derouane, Christel Fontaine, Sileny Han, Greet Huygh, Michail Ignatiadis, Eline Naert, Kevin Punie, Annelies Requilé, Christos Sotiriou, Wiebren Tjalma, Koen Traen, Yannick Van Herck, Hans Wildiers

Читать у издателя →

Похожие статьи